FOR PHARMACEUTICAL BRAND & MARKETING TEAMS The Campaign Isn't Slow.
The Review Queue Is.
Pharmaceutical digital marketing built around the review process from day one, not fighting it after the fact. SEO, HCP and DTC paid media, content, reputation, and PR for brand teams who need speed without triggering an OPDP letter.
Grow your Brand
Built Around the Queue, Not Around the Guesswork
Every pharma marketer knows the cycle: a campaign gets built, submitted to Medical, Legal, and Regulatory review, and comes back three weeks later unrecognizable, or worse, rejected outright because nobody flagged the fair-balance issue before it reached Legal.
Pharmaceutical digital marketing built without that review cycle in mind isn’t actually pharmaceutical marketing, it’s a redo waiting to happen. Every asset here is built with MLR requirements in view from the first draft, so what reaches the review queue is more likely to survive it.
The BundleOne Partner Across the Full Pharma Marketing Mix
Five disciplines, each built around the specific regulatory constraints that apply to it, not a generic healthcare template with a pharma label on top.
Why Pharma Brand Teams Choose A Partner Who Understands the
Review Queue, Not Just the Campaign
Medcore Digital works with pharmaceutical brand and marketing teams specifically, not as a general healthcare agency that occasionally takes a pharma client.
Built to Survive MLR, Not Just Reach It
Assets are structured with the review committee’s actual concerns in mind from the first draft, so fewer rounds are needed to get to a version that clears.
OPDP-Conscious by Default
Fair-balance and risk-disclosure requirements the FDA’s Office of Prescription Drug Promotion looks for are built in from the start, not patched in after a warning letter risk gets flagged.
No Off-Label Promotion, No Exceptions
Content and campaigns stay within the approved label, full stop, regardless of what a competitor’s messaging might imply.
Scoped for Emerging Brands & Enterprises
A single-product launch gets the same regulatory discipline as a multi-brand portfolio, scoped to what that team actually needs.
Emerging Brand Or Global EnterpriseBuilt for Where the Brand Actually Is
A specialty biotech launching its first product and a global pharma enterprise managing a mature portfolio are solving different problems, even when the regulatory rules are the same.
01
Emerging & Specialty Pharma
A first launch needs a partner who can move fast without skipping the review step that actually protects the launch.
02
Global & Enterprise Pharma
A mature portfolio needs consistency across brands and geographies, and a partner who isn’t relearning the MLR process with every new asset.
Questions Frequently Asked Questions
Yes. Strategies scale for emerging specialty pharma companies and global enterprise brands alike, scoped to the size and complexity of the portfolio.
In practice, yes. General healthcare SEO doesn’t have to account for OPDP fair-balance requirements, off-label promotion restrictions, or the difference between branded and unbranded content, all of which shape what a pharma SEO page can actually say. A pharmaceutical SEO company builds for those constraints from the outset rather than adapting general healthcare content after the fact.
MLR stands for Medical, Legal, and Regulatory review, the internal approval process nearly every pharma marketing asset has to pass before it can publish. It’s the single biggest variable in a pharma campaign timeline. Building assets with MLR’s likely concerns addressed from the first draft, rather than discovering them after submission, is what actually shortens the cycle.
Yes. Campaigns, SEO, paid media, and content are all built with MLR review, OPDP fair-balance requirements, and off-label promotion restrictions in mind from the start, not treated as a final check before launch.
Both, and they’re treated as genuinely different problems. HCP campaigns can carry more clinical detail and assume a professional audience; DTC campaigns require patient-friendly language and the risk disclosures that come with direct-to-consumer promotion.
Sunshine Act, or Open Payments, considerations are built into event and PR planning wherever a pharma brand interacts with physicians, such as conference sponsorships, speaker fees, or meals, so reportable interactions get flagged as part of the plan rather than discovered afterward.
Paid media typically shows measurable engagement within 30 to 60 days, while SEO gains compound over 3 to 6 months. MLR review timelines vary by organization and can affect how quickly a given asset actually launches.
Pharma SEO, HCP and DTC paid media, content marketing, reputation management, and PR and medical communications, run as one coordinated strategy rather than five separate vendor relationships.
Get the Campaign to Market Without Losing to the Review Queue
Get pharmaceutical digital marketing built around MLR and OPDP from the first draft, across SEO, paid media, content, reputation, and PR. Start with a free audit of where the current marketing mix is creating review friction.
